VIKING THERAPEUTICS INC (VKTX)
US92686J1060 - Common Stock
Overall VKTX gets a fundamental rating of 3 out of 10. We evaluated VKTX against 561 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VKTX had negative earnings in the past year.
VKTX had a negative operating cash flow in the past year.
In the past 5 years VKTX always reported negative net income.
VKTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -10.57%, VKTX belongs to the best of the industry, outperforming 87.03% of the companies in the same industry.
The Return On Equity of VKTX (-10.88%) is better than 89.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.57% | ||
| ROE | -10.88% | ||
| ROIC | N/A |
ROA(3y)-30.09%
ROA(5y)-22.95%
ROE(3y)-33.1%
ROE(5y)-24.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VKTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VKTX has more shares outstanding than it did 1 year ago.
VKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 108.48 indicates that VKTX is not in any danger for bankruptcy at the moment.
The Altman-Z score of VKTX (108.48) is better than 99.64% of its industry peers.
VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 108.48 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
VKTX has a Current Ratio of 36.47. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
VKTX has a Current ratio of 36.47. This is amongst the best in the industry. VKTX outperforms 98.74% of its industry peers.
A Quick Ratio of 36.47 indicates that VKTX has no problem at all paying its short term obligations.
VKTX's Quick ratio of 36.47 is amongst the best of the industry. VKTX outperforms 98.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 36.47 | ||
| Quick Ratio | 36.47 |
3. Growth
3.1 Past
The earnings per share for VKTX have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 13.59% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.12%
EPS Next 2Y-27.91%
EPS Next 3Y-25.61%
EPS Next 5Y13.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VKTX's earnings are expected to decrease with -25.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.91%
EPS Next 3Y-25.61%
5. Dividend
5.1 Amount
VKTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIKING THERAPEUTICS INC
NASDAQ:VKTX (1/6/2025, 8:00:01 PM)
After market: 42.7 +0.17 (+0.4%)42.53
-0.36 (-0.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.79%
Inst Owner Change0%
Ins Owners2.77%
Ins Owner Change0.27%
Market Cap4.74B
Analysts87.62
Price Target115.65 (171.93%)
Short Float %17.75%
Short Ratio3.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.87%
Min EPS beat(2)14.36%
Max EPS beat(2)27.38%
EPS beat(4)4
Avg EPS beat(4)13.32%
Min EPS beat(4)3.25%
Max EPS beat(4)27.38%
EPS beat(8)5
Avg EPS beat(8)5.18%
EPS beat(12)7
Avg EPS beat(12)4.71%
EPS beat(16)10
Avg EPS beat(16)4.58%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.39%
PT rev (3m)-0.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.54%
EPS NY rev (1m)0.4%
EPS NY rev (3m)2.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.2 | ||
| P/tB | 5.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.93
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS8.18
TBVpS8.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.57% | ||
| ROE | -10.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-30.09%
ROA(5y)-22.95%
ROE(3y)-33.1%
ROE(5y)-24.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 36.47 | ||
| Quick Ratio | 36.47 | ||
| Altman-Z | 108.48 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
EPS Next Y-8.12%
EPS Next 2Y-27.91%
EPS Next 3Y-25.61%
EPS Next 5Y13.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.55%
EBIT Next 3Y-31.37%
EBIT Next 5Y-16.47%
FCF growth 1Y-49.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.03%
OCF growth 3YN/A
OCF growth 5YN/A